Announcements Trials
Browse Landscape

Status

Withdrawn 4Terminated 3Recruiting 3No longer available 2Approved for marketing 1

Sponsor Class

INDUSTRY 2

Study Type

Expanded_access 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioma 2

Interventions

TIC10 compound 23-Iodobenzylguanidine 2tucatinib 1rindopepimut 1pembrolizumab 1pegfilgrastim 1paclitaxel-Angiopep-2 conjugate 1omburtamab I-131 1mogamulizumab 1gallium maltolate 1fluorodopa F 18 1efineptakin alfa 1avapritinib 1Vorinostat 1Potassium Iodide 1OKN 007 1Ketoconazole 1Ipilimumab 1Granulocyte Colony-Stimulating Factor 1Fenretinide 1Cancer Vaccines 1Adjuvants, Immunologic 1ABT-414 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
No longer available × TIC10 compound × CNS × Clear all
NCT05392374 2022-05-26

Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas

Jazz Pharmaceuticals

No longer available
1 FDA
CNS

Glioma

NCT03134131 2022-03-14

Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas

Jazz Pharmaceuticals

No longer available
1 FDA
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡